Oculis (NASDAQ:OCS) Stock Price Expected to Rise, HC Wainwright Analyst Says

Oculis (NASDAQ:OCS) had its price target upped by research analysts at HC Wainwright from $33.00 to $36.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 93.97% from the stock’s previous close.

Several other equities research analysts have also issued reports on OCS. Wall Street Zen lowered Oculis from a “hold” rating to a “sell” rating in a research note on Sunday, September 21st. Needham & Company LLC initiated coverage on Oculis in a research report on Wednesday, August 27th. They issued a “buy” rating and a $36.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research note on Saturday, September 27th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.50.

Oculis Trading Up 5.6%

Shares of Oculis stock opened at $18.56 on Tuesday. The company has a 50 day simple moving average of $17.52 and a two-hundred day simple moving average of $18.06. The firm has a market cap of $810.33 million, a PE ratio of -6.95 and a beta of 0.29. Oculis has a 1 year low of $13.60 and a 1 year high of $23.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.55 and a quick ratio of 4.55.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Thursday, August 21st. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.06). Oculis had a negative net margin of 13,958.12% and a negative return on equity of 90.31%. The company had revenue of $0.25 million for the quarter, compared to analysts’ expectations of $0.14 million. Analysts expect that Oculis will post -2.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE increased its stake in shares of Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after buying an additional 10,667 shares during the period. Kestra Private Wealth Services LLC bought a new stake in Oculis in the 1st quarter worth $234,000. Aberdeen Group plc grew its holdings in Oculis by 24.1% in the 1st quarter. Aberdeen Group plc now owns 1,253,119 shares of the company’s stock worth $23,847,000 after acquiring an additional 243,695 shares during the last quarter. SR One Capital Management LP purchased a new position in shares of Oculis in the first quarter valued at about $6,137,000. Finally, Pivotal bioVenture Partners Investment Advisor LLC raised its stake in shares of Oculis by 32.4% during the first quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company’s stock valued at $43,784,000 after acquiring an additional 563,078 shares during the last quarter. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.